Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04663282 · ClinicalTrials.gov registry record · Phase 2

A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics

A Phase 2 study of Type 2 Diabetes, sponsored by Jiangsu HengRui Medicine Co..

Completed
Registry status
Phase 2
Development phase
179
Enrollment target
20
Study locations

NCT04663282 is a Phase 2 study of Type 2 Diabetes that has completed, run by Jiangsu HengRui Medicine Co.. The registered enrollment target is 179 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04663282, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by Jiangsu HengRui Medicine Co..

COMPLETED
Registry status
Phase 2
Development phase
179 participants
Enrollment target
20
Study locations

Study Summary

The study is being conducted to evaluate the efficacy and safety of IND068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with one or two oral antidiabetics compared to insulin degludec QD for 16 weeks.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Insulin Degludec
  • DRUG INS068 injection

Study Locations (20)

California

  • National Research Institute - Huntington Park - Huntington Park
  • Clinical Trials Research - Lincoln
  • Torrance Clinical Research Institute Inc - Lomita
  • National Research Institute - Wilshire - Los Angeles

Florida

  • ALL Medical Research, LLC - Cooper City
  • New Generation of Medical Research - Hialeah
  • Clinical Pharmacology of Miami, LLC - Miami
  • Progressive Medical Research - Port Orange

Texas

  • Juno Research, LL - Houston
  • Juno Research, LLC - Medical Center Office - Houston
  • Juno Research, LLC - Southwest Houston Site - Houston
  • Endeavor Clinical Trials - San Antonio

Ohio

  • Endocrinology Associates, Inc - Columbus
  • Prestige Clinical Research - Franklin

Victoria

  • The Royal Melbourne Hospital - Melbourne
  • Austin Health (Heidelberg Repatriation Hospital) - Melbourne

Iowa

  • Iowa Diabetes and Endocrinology Research Center - West Des Moines

Queensland

  • Core Research Group Pty Ltd - Brisbane

Beijing Municipality

  • Peking University People's Hospital - Beijing

Trial Details

FieldValue
Enrollment Target 179 participants
Start Date 2021-02-04
Est. Completion 2022-05-28
Phase Phase 2

Sponsor

Jiangsu HengRui Medicine Co.

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04663282

The ClinicalTrials.gov registry entry for NCT04663282 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (84% lower). The listed sponsor is Jiangsu HengRui Medicine Co., which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Insulin Degludec is the first listed.

NCT04663282 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT04663282 about?

NCT04663282 is a clinical study titled "A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics". The study is being conducted to evaluate the efficacy and safety of IND068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with one or two oral antidiabetics compared to insulin degludec QD for 16 weeks.

What is the current status of trial NCT04663282?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2021-02-04. Estimated completion is 2022-05-28.

What conditions does trial NCT04663282 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT04663282?

The interventions under investigation include: Insulin Degludec (DRUG), INS068 injection (DRUG).

Who is sponsoring clinical trial NCT04663282?

This trial is sponsored by Jiangsu HengRui Medicine Co., which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04663282 being conducted?

This trial has 20 study locations across California, Florida, Iowa, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.